Warren-based Tevogen Bio has been pursuing a bold growth strategy. The late-stage clinical biotechnology firm that specializes in the development of cell and gene therapies said Wednesday that, to strengthen its organizational readiness, it appointed three new members to its board of directors.
Effective immediately, the new health care leaders include Susan Podlogar, Jeffrey Feike and Lindee Goh.
“Susan, Jeffery and Lindee are wholly committed to our corporate culture of creativity, optimism, respect and equality and our aspiration to be the very first biopharma company to achieve commercial success while ensuring patient affordability,” said Tevogen CEO Dr. Ryan Saadi. “These new members bring decades of experience across critical aspects of the health care industry and will be integral to expediting the company’s current and future research endeavors and strategic business decisions.”
Podlogar is MetLife’s chief human resources officer. Podlogar champions a prepared workforce and organization for the future. She is focused on upskilling employees globally and has gained support for the Workforce of the Future Development Fund and accelerated an internal talent marketplace. Podlogar also serves on MetLife Foundation’s board of directors. She also is called upon to provide thought leadership on innovative HR practices to various governmental and educational institutions. Previously, Podlogar served as the global vice president of human resources for Johnson & Johnson.
Feike is a public health servant-leader with 30-plus years of experience as CEO of multiple hospitals. In his career he has overseen the development of hospitals, outpatient clinics and EMS systems coupled with a wide array of medical programs including cancer centers, stroke centers and trauma centers. His hospitals have received national recognition from both the Joint Commission and the VHA for outstanding clinical excellence. He is past chairman of the Nevada Hospital Association, and a 30-year member of the American College of Healthcare Executives.
Goh leads Tapestry Networks’ health care practice, working with public and private sector leaders to develop effective strategies to improve clinical outcomes while fostering sustainable health care innovation. In doing this, she co-led several working groups, covering topics including the design and implementation of the parallel scientific advice process, approach to regulation and reimbursement in Europe, recommendations to address innovation, diagnostics, & infrastructure challenges of Alzheimer’s disease, molecular diagnostic quality assurance in precision medicine, health care financing and payment models in oncology and rare diseases, and multicancer early detection consortium. Before Tapestry Networks, Goh led teams at the Boston Consulting Group, working in biopharma, payer and provider spaces.